Oncodesign Services and Nexus BioQuest partner to give biotechs a clearer route

With shared experience across oncology, inflammation and autoimmunity, the two companies will be able to contribute complementary scientific approaches within individual development programs

Oncodesign Services and Nexus BioQuest have formed a partnership connecting their respective in vitro and in vivo expertise, giving biotech companies a clearer route to specialist support as preclinical programs progress.

The collaboration links Nexus BioQuest’s human-relevant in vitro expertise with Oncodesign Services’ three decades of experience in in vivo pharmacology. 

With shared experience across oncology, inflammation and autoimmunity, the two companies will be able to contribute complementary scientific approaches within individual development programs. 

Nexus BioQuest brings expertise in human primary cell-based immunology, combining translational 2D and 3D models that integrate immune cells and relevant tissue targets with validated and bespoke assay development across immuno-oncology, inflammation and autoimmunity. 

Oncodesign Services' capabilities include syngeneic, patient-derived xenograft (PDX), cell-derived xenograft (CDX) and humanized immune system in vivo models, inflammatory disease models, radiopharmaceuticals, and preclinical imaging. 

These complementary capabilities give biotech teams access to different types of preclinical evidence to support informed decision-making as their scientific requirements evolve.

Endometriosis is a proof-of-concept for this joint approach and an emerging therapeutic area for immune targeting drugs within the broader women's health and inflammation space. 

As endometriosis is a highly complex, multifactorial disease, this is an area where Nexus BioQuest’s in vitro primary cell inflammatory models can be used to complement Oncodesign Services’ validated in vivo endometriosis models that can assess pathophysiological endpoints including lesion development, fibrosis and inflammatory responses. 

Aidan Synnott, CEO at Oncodesign Services, said: “For biotech teams, the challenge is often not finding another CRO, but finding the right expertise for the scientific question they need to answer next. We know the Nexus BioQuest team and the quality of its science, which means we can make an introduction with confidence when a program needs capabilities outside of our specialist scope,” added Synnott.

Will Parish, CEO at Nexus BioQuest, said: “Early drug discovery rarely comes down to a single experiment or model. Having access to trusted specialist expertise in both areas gives biotech teams a clearer route to the support they need at different points in preclinical development, helping them make more informed decisions about where to place their work.”